No Evidence of Data Manipulation in Science Publication on Simufilam

Cassava Sciences Inc., (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of Prevention of Alzheimer's Disease (JPAD) that there is no convincing evidence to support allegations of data manipulation in a 2020 paper on simufilam co-authored by the Company’s personnel and its science collaborators.